Sexual Health Peptides

Sexual health peptides primarily act through two distinct but interconnected pathways. The melanocortin pathway involves activation of MC3R and MC4R receptors in the hypothalamus and limbic system. Alpha-melanocyte-stimulating hormone (alpha-MSH) and its synthetic analogues bind these receptors to initiate downstream signaling cascades that promote sexual arousal and desire. PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH that selectively activates MC4R, triggering dopaminergic and oxytocinergic pathways in the medial preoptic area and paraventricular nucleus — brain regions directly involved in sexual motivation and arousal. The hypothalamic-pituitary-gonadal (HPG) axis pathway centers on kisspeptin, a neuropeptide produced by KISS1 neurons in the arcuate nucleus and anteroventral periventricular nucleus. Kisspeptin binds the GPR54 (KISS1R) receptor on GnRH neurons, stimulating pulsatile gonadotropin-releasing hormone (GnRH) secretion. This in turn drives luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the anterior pituitary, which stimulates gonadal steroidogenesis and gametogenesis. Kisspeptin is the master regulator of reproductive neuroendocrinology — it integrates metabolic, circadian, and stress signals to gate fertility. Melanotan II operates through a broader melanocortin receptor profile, activating MC1R (pigmentation), MC3R, MC4R, and MC5R. Its sexual function effects are mediated through the same MC3R/MC4R pathways as PT-141 but with less selectivity, which accounts for its wider side effect profile including nausea, facial flushing, and skin darkening.

PT-141 (Bremelanotide) — the only FDA-approved peptide specifically indicated for sexual dysfunction. Approved in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). PT-141 is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) derived from the linear peptide melanotan II through cyclization and truncation to improve MC4R selectivity. It is administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month. Its mechanism of action — central nervous system melanocortin activation — makes it fundamentally different from PDE5 inhibitors and represents the first drug to treat sexual desire through brain-level pathways. Kisspeptin-10 — the bioactive C-terminal decapeptide of full-length kisspeptin (kisspeptin-54), which binds GPR54 to stimulate GnRH pulsatility. Research at Imperial College London and other institutions has demonstrated that kisspeptin infusion can restore LH pulsatility in women with hypothalamic amenorrhea, trigger ovulation in IVF protocols as an alternative to hCG (with lower risk of ovarian hyperstimulation syndrome), and increase sexual arousal when administered to healthy men during fMRI brain imaging studies. Kisspeptin is being actively investigated as a diagnostic tool for pubertal disorders and as a therapeutic agent for functional hypothalamic amenorrhea and assisted reproduction. Melanotan II — a cyclic heptapeptide analogue of alpha-MSH that was originally developed at the University of Arizona for skin tanning but was found to have potent pro-erectile and pro-sexual effects through MC3R/MC4R activation. It has never received regulatory approval and is not in active clinical development for sexual function, though it remains widely available in the research peptide market. Its lack of receptor selectivity produces a broader effect profile than PT-141, including skin pigmentation changes, appetite suppression, nausea, and facial flushing alongside its sexual function effects. Melanotan I (Afamelanotide) — a linear alpha-MSH analogue with higher MC1R selectivity. FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), not for sexual function. Included here because it is sometimes confused with Melanotan II, but it has minimal MC4R activity and negligible sexual function effects at standard dosing. Bremelanotide — the INN (international nonproprietary name) for PT-141. Listed separately because some literature and databases reference it under this name rather than PT-141.

PT-141/bremelanotide has the most robust clinical evidence in this class. Two pivotal phase III trials (RECONNECT studies, n=1,247 premenopausal women with HSDD) demonstrated statistically significant improvements in sexual desire as measured by the Female Sexual Function Index (FSDI) desire domain and reductions in distress related to low sexual desire on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The treatment effect was modest but consistent: approximately 0.3-point improvement in desire score and 25% of patients achieving clinically meaningful improvement versus 17% with placebo. Earlier phase II studies in men with erectile dysfunction showed pro-erectile effects, but development for male sexual dysfunction was not pursued to phase III. Notably, PT-141 showed efficacy in men who did not respond to sildenafil, suggesting its central mechanism addresses a different aspect of sexual function. Kisspeptin research is primarily academic and investigator-initiated rather than pharmaceutical industry-driven. Key findings include: Dhillo et al. (2005) first demonstrated that kisspeptin-54 stimulates gonadotropin secretion in healthy men; Jayasena et al. (2013, 2014) showed kisspeptin infusion can safely trigger oocyte maturation in IVF with significantly reduced ovarian hyperstimulation risk compared to hCG; Comninos et al. (2017) demonstrated that kisspeptin-54 enhances limbic brain activity in response to sexual images in healthy men, suggesting a role in sexual arousal beyond pure reproductive endocrinology. Phase II trials are ongoing for kisspeptin as an IVF trigger and for hypothalamic amenorrhea treatment. Melanotan II has no phase III data and its clinical development was abandoned in favor of the more selective PT-141. Phase I/II studies at the University of Arizona in the late 1990s documented spontaneous erections and increased sexual desire in male subjects, which led to the development of PT-141 as a more targeted derivative. The absence of regulatory-grade clinical data for Melanotan II means that all efficacy and safety information comes from early-phase studies, case reports, and observational data from self-administration.

PT-141/bremelanotide carries an FDA black box warning for transient increases in blood pressure. Systolic BP typically rises 2-3 mmHg and diastolic 1-2 mmHg, peaking around 2-4 hours post-dose and resolving within 12 hours. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. The most common side effects in clinical trials were nausea (40% of patients, usually mild and dose-dependent), flushing (20%), injection site reactions (13%), and headache (11%). Nausea tends to diminish with subsequent doses. PT-141 is limited to 8 doses per month due to the potential for focal hyperpigmentation with more frequent use. It should not be used with naltrexone or other opioid antagonists due to a pharmacodynamic interaction. Melanotan II carries all the side effects of PT-141 plus additional concerns related to its broader receptor profile. Nausea is more common and often more severe. Progressive skin darkening occurs with repeated use due to MC1R activation and is unpredictable — it may be patchy, may darken existing moles (raising dermatological monitoring concerns), and is slow to reverse after discontinuation. There is a theoretical but unproven concern that MC1R-driven melanocyte stimulation could increase melanoma risk, particularly in individuals with many atypical nevi. Facial flushing, fatigue, and yawning are common acute effects. Kisspeptin has shown an excellent safety profile in clinical studies to date. Because it stimulates endogenous GnRH pulsatility rather than providing exogenous gonadotropins, the risk of ovarian hyperstimulation syndrome (OHSS) appears significantly lower than with hCG trigger protocols in IVF. Short-term side effects are minimal. Long-term safety data is limited as most studies have used single-dose or short-duration infusion protocols. All peptides in this class should be considered contraindicated during pregnancy. Individuals with hormone-sensitive cancers, cardiovascular disease, or uncontrolled hypertension should avoid melanocortin agonists. Melanotan II users should have dermatological monitoring for changes in moles or pigmented lesions.